Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • medical dermatology

    - PMLiVE

    Sandoz to acquire Just-Evotec Biologics to strengthen biosimilar development and manufacturing capabilities

    Acquisition will add in-house continuous manufacturing expertise and expand Sandoz’s biosimilar production capacity

    - PMLiVE

    Almirall and Absci expand AI dermatological drug discovery partnership

    The alliance has already led to the delivery of functional antibody leads against a difficult-to-drug target

    - PMLiVE

    NHS programme to give melanoma patients fast-track access to skin cancer vaccine

    The phase 2 study will evaluate Scancell's iSCIB1+ in patients with advanced unresectable melanoma

    - PMLiVE

    Almirall hosts Skin Academy to advance skin science and dermatology treatments

    The conference will cover actinic keratosis, psoriasis, atopic dermatitis and other skin diseases

    regeneron headquarters

    Regeneron shares positive phase 3 results for Libtayo in high-risk skin cancer

    Approximately 1.8 million cases of cutaneous squamous cell carcinoma are diagnosed in the US every year

    - PMLiVE

    Eli Lilly/Almirall share positive long-term results for Ebglyss in atopic dermatitis

    The inflammatory skin condition occurs in approximately 7.3% of adults in the US

    - PMLiVE

    Merck shares positive ten-year results for Keytruda in advanced melanoma

    More than 100,640 cases of the skin cancer are expected to be diagnosed in the US this year

    - PMLiVE

    Almirall announces NICE recommendation for Ebglyss in atopic dermatitis

    The inflammatory skin condition affects about 5.2 million adults and 2.5 million children in the UK

    - PMLiVE

    Almirall’s Ilumetri shown to improve and maintain well-being in plaque psoriasis patients

    Nearly 77% of psoriasis patients report that the condition negatively affects their well-being

    - PMLiVE

    Almirall’s Klisyri receives expanded FDA approval to treat actinic keratosis

    The precancerous condition is responsible for an estimated 60% of all squamous cell carcinoma cases

    - PMLiVE

    Moderna/Merck share positive three-year results for investigational skin cancer vaccine

    More than 100,000 new cases of melanoma are expected to be diagnosed in the US in 2024

    - PMLiVE

    Almirall survey reveals limited knowledge of most common precancerous skin condition

    An estimated 60% of squamous cell carcinoma cases, the second most common skin cancer, develop from AK lesions

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links